Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Moodys
Baxter
Dow
Johnson and Johnson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Dapagliflozin; Saxagliptin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01606007 Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes Completed AstraZeneca Phase 3 2012-07-01 The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of this treatment will also be studied.
NCT01619059 Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed AstraZeneca Phase 3 2012-06-01 The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.
NCT01646320 Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed AstraZeneca Phase 3 2012-09-01 The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.
NCT01662999 Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants Completed AstraZeneca Phase 1 2012-08-01 The purpose of this study is to evaluate whether the pharmacokinetics (body concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when they are administered together
NCT02060201 Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC) Completed AstraZeneca Phase 1 2014-02-01 The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and Dapagliflozin from a 2.5-mg Saxagliptin/5-mg Dapagliflozin FDC tablet after oral administration relative to 2.5-mg Saxagliptin and 5-mg Dapagliflozin tablets administered orally together in the fasted state and to demonstrate the BE of Saxagliptin and Dapagliflozin from a 5-mg Saxagliptin/10-mg Dapagliflozin FDC tablet after oral administration relative to 5-mg Saxagliptin and 10-mg Dapagliflozin tablets administered orally together in the fasted state. Demonstrating bioequivalence refers to showing that the FDC tablet and co-administration of the individual components yield similar blood levels/concentrations of the drug and are handled by the body similarly.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dapagliflozin; Saxagliptin Hydrochloride

Condition Name

Condition Name for Dapagliflozin; Saxagliptin Hydrochloride
Intervention Trials
Type 2 Diabetes Mellitus 8
Type 2 Diabetes 5
Diabetes Mellitus, Type 2 4
Type2 Diabetes Mellitus 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dapagliflozin; Saxagliptin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 22
Diabetes Mellitus 22
Hypoglycemia 1
Cardiovascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dapagliflozin; Saxagliptin Hydrochloride

Trials by Country

Trials by Country for Dapagliflozin; Saxagliptin Hydrochloride
Location Trials
United States 134
Canada 24
Mexico 16
South Africa 8
Poland 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dapagliflozin; Saxagliptin Hydrochloride
Location Trials
Texas 10
California 8
Florida 8
South Carolina 7
Arizona 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dapagliflozin; Saxagliptin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Dapagliflozin; Saxagliptin Hydrochloride
Clinical Trial Phase Trials
Phase 4 5
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dapagliflozin; Saxagliptin Hydrochloride
Clinical Trial Phase Trials
Completed 8
Recruiting 7
Not yet recruiting 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dapagliflozin; Saxagliptin Hydrochloride

Sponsor Name

Sponsor Name for Dapagliflozin; Saxagliptin Hydrochloride
Sponsor Trials
AstraZeneca 19
The University of Texas Health Science Center at San Antonio 2
Parexel 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dapagliflozin; Saxagliptin Hydrochloride
Sponsor Trials
Industry 21
Other 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Colorcon
McKinsey
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.